$34.99
0.0850.24%
Last update: Nov 10, 10:19 AM
Maze Therapeutics Inc
MAZENASDAQ
Maze Therapeutics rose 14.5% from $30.49 to $34.91, ahead of the S&P 500's +10.5%. Its worst day was Mar 25 (−35.2%), and its low came Sep 21 at $22.39.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Maze Therapeutics closed at its highest level of the year, 70.0% above where the year started.
+2.8% · S&P 500 −1.5%
EPS of $-0.65 beat the $-0.71 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−35.2%, the year's worst day, on 8M shares, the year's heaviest volume · S&P 500 +0.6%
EPS of $-0.45 beat the $-0.59 estimate on $20.0M revenue (est. $10.1M).
+4.6% · S&P 500 +0.6%
EPS of $-0.76 missed the $-0.71 estimate on $0.00 revenue (est. $1.8M).
+0.8% · S&P 500 +0.3%
Maze Therapeutics closed at its lowest level of the year, 26.6% below where the year started.
−0.6% · S&P 500 +1.6%
Where it ended: a close of $34.91 on Nov 9, 2026.
Nothing in the past 12 months.
All MAZE dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MAZE and SPY from Benzinga historical bars. Not investment advice.
